The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

Loris R. Lopetuso, Marco Napoli, Gianenrico Rizzatti, Antonio Gasbarrini

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Introduction: The gastrointestinal tract acts as a functional unit organized as a semipermeable multilayer system, in which commensal gut microbiota represents the anatomical barrier. Recently, several studies have highlighted the involvement of gut microbiota in inflammatory bowel diseases (IBD) pathogenesis, in sustaining gut barrier chronic inflammation, and in conditioning disease course and therapeutical response. This evidence provides a rationale for treating patients with gut microbiota modifiers. Among these, Rifaximin represents a non-traditional antibiotic able to act as a ‘eubiotic’ on intestinal barrier. Area covered: The purpose of this narrative review is to explore the impact of Rifaximin on gut barrier and gut microbiota in IBD, in particular in Crohn’s disease (CD), and to analyze its potential therapeutic applications. Expert opinion: The possibility of a beneficial activity of Rifaximin in chronic intestinal inflammation and CD has been debated and evaluated with different studies having obtained promising but still preliminary data. Larger trials are therefore needed. This gut-specific antibiotic could represent an alternative to systemic antibiotics thanks to its favorable safety profile and promising efficacy data. Rifaximin could exert, when appropriate, a synergic effect with immunomodulators in IBD, acting on both the microbial and the immunological sides of gut barrier impairment.

Original languageEnglish
Pages (from-to)543-551
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume27
Issue number6
DOIs
Publication statusPublished - Jun 3 2018

Fingerprint

rifaximin
Crohn Disease
Inflammatory Bowel Diseases
Inflammation
Anti-Bacterial Agents
Intestinal Diseases
Expert Testimony
Immunologic Factors
Therapeutics
Gastrointestinal Tract
Safety
Gastrointestinal Microbiome

Keywords

  • chronic inflammation
  • Crohn’s disease
  • gut barrier
  • gut microbiota
  • IBD
  • inflammatory bowel disease
  • Rifaximin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. / Lopetuso, Loris R.; Napoli, Marco; Rizzatti, Gianenrico; Gasbarrini, Antonio.

In: Expert Opinion on Investigational Drugs, Vol. 27, No. 6, 03.06.2018, p. 543-551.

Research output: Contribution to journalReview article

@article{c2fc3d5926e542d5a1eb994d4156dcb6,
title = "The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease",
abstract = "Introduction: The gastrointestinal tract acts as a functional unit organized as a semipermeable multilayer system, in which commensal gut microbiota represents the anatomical barrier. Recently, several studies have highlighted the involvement of gut microbiota in inflammatory bowel diseases (IBD) pathogenesis, in sustaining gut barrier chronic inflammation, and in conditioning disease course and therapeutical response. This evidence provides a rationale for treating patients with gut microbiota modifiers. Among these, Rifaximin represents a non-traditional antibiotic able to act as a ‘eubiotic’ on intestinal barrier. Area covered: The purpose of this narrative review is to explore the impact of Rifaximin on gut barrier and gut microbiota in IBD, in particular in Crohn’s disease (CD), and to analyze its potential therapeutic applications. Expert opinion: The possibility of a beneficial activity of Rifaximin in chronic intestinal inflammation and CD has been debated and evaluated with different studies having obtained promising but still preliminary data. Larger trials are therefore needed. This gut-specific antibiotic could represent an alternative to systemic antibiotics thanks to its favorable safety profile and promising efficacy data. Rifaximin could exert, when appropriate, a synergic effect with immunomodulators in IBD, acting on both the microbial and the immunological sides of gut barrier impairment.",
keywords = "chronic inflammation, Crohn’s disease, gut barrier, gut microbiota, IBD, inflammatory bowel disease, Rifaximin",
author = "Lopetuso, {Loris R.} and Marco Napoli and Gianenrico Rizzatti and Antonio Gasbarrini",
year = "2018",
month = "6",
day = "3",
doi = "10.1080/13543784.2018.1483333",
language = "English",
volume = "27",
pages = "543--551",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease

AU - Lopetuso, Loris R.

AU - Napoli, Marco

AU - Rizzatti, Gianenrico

AU - Gasbarrini, Antonio

PY - 2018/6/3

Y1 - 2018/6/3

N2 - Introduction: The gastrointestinal tract acts as a functional unit organized as a semipermeable multilayer system, in which commensal gut microbiota represents the anatomical barrier. Recently, several studies have highlighted the involvement of gut microbiota in inflammatory bowel diseases (IBD) pathogenesis, in sustaining gut barrier chronic inflammation, and in conditioning disease course and therapeutical response. This evidence provides a rationale for treating patients with gut microbiota modifiers. Among these, Rifaximin represents a non-traditional antibiotic able to act as a ‘eubiotic’ on intestinal barrier. Area covered: The purpose of this narrative review is to explore the impact of Rifaximin on gut barrier and gut microbiota in IBD, in particular in Crohn’s disease (CD), and to analyze its potential therapeutic applications. Expert opinion: The possibility of a beneficial activity of Rifaximin in chronic intestinal inflammation and CD has been debated and evaluated with different studies having obtained promising but still preliminary data. Larger trials are therefore needed. This gut-specific antibiotic could represent an alternative to systemic antibiotics thanks to its favorable safety profile and promising efficacy data. Rifaximin could exert, when appropriate, a synergic effect with immunomodulators in IBD, acting on both the microbial and the immunological sides of gut barrier impairment.

AB - Introduction: The gastrointestinal tract acts as a functional unit organized as a semipermeable multilayer system, in which commensal gut microbiota represents the anatomical barrier. Recently, several studies have highlighted the involvement of gut microbiota in inflammatory bowel diseases (IBD) pathogenesis, in sustaining gut barrier chronic inflammation, and in conditioning disease course and therapeutical response. This evidence provides a rationale for treating patients with gut microbiota modifiers. Among these, Rifaximin represents a non-traditional antibiotic able to act as a ‘eubiotic’ on intestinal barrier. Area covered: The purpose of this narrative review is to explore the impact of Rifaximin on gut barrier and gut microbiota in IBD, in particular in Crohn’s disease (CD), and to analyze its potential therapeutic applications. Expert opinion: The possibility of a beneficial activity of Rifaximin in chronic intestinal inflammation and CD has been debated and evaluated with different studies having obtained promising but still preliminary data. Larger trials are therefore needed. This gut-specific antibiotic could represent an alternative to systemic antibiotics thanks to its favorable safety profile and promising efficacy data. Rifaximin could exert, when appropriate, a synergic effect with immunomodulators in IBD, acting on both the microbial and the immunological sides of gut barrier impairment.

KW - chronic inflammation

KW - Crohn’s disease

KW - gut barrier

KW - gut microbiota

KW - IBD

KW - inflammatory bowel disease

KW - Rifaximin

UR - http://www.scopus.com/inward/record.url?scp=85050219660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050219660&partnerID=8YFLogxK

U2 - 10.1080/13543784.2018.1483333

DO - 10.1080/13543784.2018.1483333

M3 - Review article

C2 - 29865875

AN - SCOPUS:85050219660

VL - 27

SP - 543

EP - 551

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 6

ER -